Latest Insider Transactions at Janux Therapeutics, Inc. (JANX)
This section provides a real-time view of insider transactions for Janux Therapeutics, Inc. (JANX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Janux Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Janux Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 11
2025
|
Winston Kung |
BUY
Grant, award, or other acquisition
|
Direct |
3,750
+37.5%
|
-
|
|
Jun 11
2025
|
Jake Simson |
BUY
Grant, award, or other acquisition
|
Direct |
3,750
+37.5%
|
-
|
|
Jun 11
2025
|
Alana B. Mc Nulty |
BUY
Grant, award, or other acquisition
|
Direct |
3,750
+37.5%
|
-
|
|
Jun 11
2025
|
Natasha Hernday |
BUY
Grant, award, or other acquisition
|
Direct |
3,750
+30.05%
|
-
|
|
Jun 11
2025
|
Sheila Gujrathi |
BUY
Grant, award, or other acquisition
|
Direct |
3,750
+3.06%
|
-
|
|
Jun 11
2025
|
Eric Dobmeier |
BUY
Grant, award, or other acquisition
|
Direct |
3,750
+27.31%
|
-
|
|
Jun 11
2025
|
Vickie L Capps |
BUY
Grant, award, or other acquisition
|
Direct |
3,750
+4.82%
|
-
|
|
Jun 11
2025
|
Ronald W Barrett |
BUY
Grant, award, or other acquisition
|
Direct |
3,750
+37.5%
|
-
|
|
Jun 11
2025
|
Ra Capital Management, L.P. |
BUY
Grant, award, or other acquisition
|
Indirect |
3,750
+37.5%
|
-
|
|
Jun 02
2025
|
Janeen Noel Doyle Chief Corp. & Bus. Dev. Ofcr |
BUY
Grant, award, or other acquisition
|
Direct |
44,000
+50.0%
|
-
|
|
May 01
2025
|
Andrew Hollman Meyer Chief Business Officer |
SELL
Open market or private sale
|
Direct |
3,333
-1.96%
|
$106,656
$32.28 P/Share
|
|
May 01
2025
|
Andrew Hollman Meyer Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,333
+3.75%
|
$13,332
$4.21 P/Share
|
|
Apr 21
2025
|
Andrew Hollman Meyer Chief Business Officer |
SELL
Open market or private sale
|
Direct |
3,334
-3.9%
|
$100,020
$30.0 P/Share
|
|
Apr 21
2025
|
Andrew Hollman Meyer Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,334
+3.75%
|
$13,336
$4.21 P/Share
|
|
Mar 07
2025
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
110,206
+1.08%
|
$3,416,386
$31.02 P/Share
|
|
Mar 06
2025
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
372,093
+3.58%
|
$11,162,790
$30.78 P/Share
|
|
Mar 05
2025
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
341,742
+1.73%
|
$10,252,260
$30.93 P/Share
|
|
Mar 03
2025
|
Andrew Hollman Meyer Chief Business Officer |
SELL
Open market or private sale
|
Direct |
3,334
-1.97%
|
$106,688
$32.36 P/Share
|
|
Mar 03
2025
|
Andrew Hollman Meyer Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,334
+3.75%
|
$13,336
$4.21 P/Share
|
|
Feb 03
2025
|
Andrew Hollman Meyer Chief Business Officer |
SELL
Open market or private sale
|
Direct |
3,334
-1.31%
|
$140,028
$42.82 P/Share
|
|
Feb 03
2025
|
Andrew Hollman Meyer Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,334
+3.75%
|
$13,336
$4.21 P/Share
|
|
Jan 07
2025
|
David Alan Campbell President and CEO |
SELL
Open market or private sale
|
Direct |
5,000
-1.68%
|
$300,000
$60.0 P/Share
|
|
Jan 02
2025
|
Maria Dobek Vice President, Accounting |
BUY
Grant, award, or other acquisition
|
Direct |
14,000
+50.0%
|
-
|
|
Jan 02
2025
|
Thomas Di Raimondo Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
24,000
+15.61%
|
-
|
|
Jan 02
2025
|
Byron Robinson Chief Strategy Officer |
BUY
Grant, award, or other acquisition
|
Direct |
28,000
+50.0%
|
-
|
|
Jan 02
2025
|
David Alan Campbell President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
81,000
+21.37%
|
-
|
|
Jan 02
2025
|
Charles M. Winter Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
23,000
+22.93%
|
-
|
|
Jan 02
2025
|
Zachariah Mc Iver Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
26,000
+50.0%
|
-
|
|
Jan 02
2025
|
Andrew Hollman Meyer Chief Business Officer |
SELL
Open market or private sale
|
Direct |
13,334
-2.94%
|
$733,370
$55.64 P/Share
|
|
Jan 02
2025
|
Andrew Hollman Meyer Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
18,000
+15.86%
|
-
|
|
Dec 24
2024
|
David Alan Campbell President and CEO |
SELL
Open market or private sale
|
Direct |
25,000
-10.33%
|
$1,400,000
$56.19 P/Share
|
|
Dec 19
2024
|
Andrew Hollman Meyer Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,881
+5.66%
|
$167,977
$17.13 P/Share
|
|
Dec 03
2024
|
David Alan Campbell President and CEO |
SELL
Open market or private sale
|
Direct |
15,000
-5.84%
|
$1,005,000
$67.0 P/Share
|
|
Nov 25
2024
|
David Alan Campbell President and CEO |
SELL
Open market or private sale
|
Direct |
25,000
-4.51%
|
$1,275,000
$51.74 P/Share
|
|
Nov 05
2024
|
Sheila Gujrathi |
BUY
Other acquisition or disposition
|
Direct |
4,611
+3.85%
|
-
|
|
Nov 05
2024
|
Vickie L Capps |
BUY
Other acquisition or disposition
|
Direct |
2,305
+3.17%
|
-
|
|
Oct 28
2024
|
David Alan Campbell President and CEO |
SELL
Open market or private sale
|
Direct |
25,000
-4.16%
|
$1,325,000
$53.58 P/Share
|
|
Oct 18
2024
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
1,200,000
+11.41%
|
$52,800,000
$44.75 P/Share
|
|
Oct 18
2024
|
Avalon Ventures Xi, L.P. |
SELL
Open market or private sale
|
Indirect |
801,751
-8.36%
|
$38,484,048
$48.74 P/Share
|
|
Oct 18
2024
|
Avalon Ventures Xi, L.P. |
SELL
Open market or private sale
|
Direct |
660,018
-8.36%
|
$31,680,864
$48.74 P/Share
|
|
Oct 17
2024
|
Avalon Ventures Xi, L.P. |
SELL
Open market or private sale
|
Direct |
1,843
-22.44%
|
$92,150
$50.02 P/Share
|
|
Oct 17
2024
|
Avalon Ventures Xi, L.P. |
BUY
Exercise of conversion of derivative security
|
Direct |
1,769
+5.41%
|
$35,380
$20.19 P/Share
|
|
Oct 16
2024
|
Avalon Ventures Xi, L.P. |
SELL
Open market or private sale
|
Direct |
100,610
-22.05%
|
$5,030,500
$50.37 P/Share
|
|
Oct 16
2024
|
Avalon Ventures Xi, L.P. |
BUY
Exercise of conversion of derivative security
|
Direct |
10,515
+15.35%
|
$210,300
$20.19 P/Share
|
|
Oct 16
2024
|
Avalon Ventures Xi, L.P. |
SELL
Open market or private sale
|
Indirect |
108,906
-1.6%
|
$5,445,300
$50.15 P/Share
|
|
Sep 30
2024
|
Avalon Ventures Xi, L.P. |
SELL
Open market or private sale
|
Direct |
958
-12.21%
|
$44,068
$46.24 P/Share
|
|
Sep 30
2024
|
Avalon Ventures Xi, L.P. |
BUY
Exercise of conversion of derivative security
|
Direct |
919
+2.94%
|
$18,380
$20.19 P/Share
|
|
Sep 27
2024
|
Avalon Ventures Xi, L.P. |
SELL
Open market or private sale
|
Direct |
49,231
-7.51%
|
$2,264,626
$46.78 P/Share
|
|
Sep 27
2024
|
Avalon Ventures Xi, L.P. |
BUY
Exercise of conversion of derivative security
|
Direct |
1,752
+5.03%
|
$35,040
$20.19 P/Share
|
|
Sep 27
2024
|
Avalon Ventures Xi, L.P. |
SELL
Open market or private sale
|
Indirect |
57,590
-0.83%
|
$2,706,730
$47.08 P/Share
|